Exact Sciences Corporation

NasdaqCM:EXAS Stock Report

Market Cap: US$19.1b

Exact Sciences Future Growth

Future criteria checks 4/6

Exact Sciences is forecast to grow earnings and revenue by 81.2% and 10.6% per annum respectively. EPS is expected to grow by 82.1% per annum. Return on equity is forecast to be 14.1% in 3 years.

Key information

81.2%

Earnings growth rate

82.11%

EPS growth rate

Biotechs earnings growth24.0%
Revenue growth rate10.6%
Future return on equity14.10%
Analyst coverage

Good

Last updated21 Nov 2025

Recent future growth updates

Recent updates

Abbott To Complete $21B M&A Deal For Exact Sciences - What Investors Should Know

Nov 20

Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 37% But Its Business Prospects Need A Lift Too

Nov 20
Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 37% But Its Business Prospects Need A Lift Too

Exact Sciences Corporation's (NASDAQ:EXAS) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Sep 08
Exact Sciences Corporation's (NASDAQ:EXAS) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Exact Sciences Corporation (NASDAQ:EXAS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

May 07
Exact Sciences Corporation (NASDAQ:EXAS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Analysts Have Made A Financial Statement On Exact Sciences Corporation's (NASDAQ:EXAS) First-Quarter Report

May 05
Analysts Have Made A Financial Statement On Exact Sciences Corporation's (NASDAQ:EXAS) First-Quarter Report
User avatar

Cologuard Plus And Oncodetect Will Improve Cancer Screening Outcomes

Cologuard Plus and rescreening efforts are key drivers of revenue growth, bolstered by payer coverage and an increasing pool of eligible individuals.

Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

Mar 19
Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

Exact Sciences: Cost Optimization And Product Strength

Aug 18

Exact Sciences: Still No Reason To Own

Jun 11

Earnings and Revenue Growth Forecasts

NasdaqCM:EXAS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20274,126236N/A71916
12/31/20263,66857N/A54621
12/31/20253,230-133N/A44321
9/30/20253,082-987247387N/A
6/30/20252,940-1,005170306N/A
3/31/20252,828-1,020194324N/A
12/31/20242,759-1,02975211N/A
9/30/20242,692-21498233N/A
6/30/20242,612-175-15119N/A
3/31/20242,535-240-20112N/A
12/31/20232,500-20432156N/A
9/30/20232,406-282-24139N/A
6/30/20232,301-432-10873N/A
3/31/20232,200-517-298-88N/A
12/31/20222,084-624-438-224N/A
9/30/20222,005-716-443-300N/A
6/30/20221,938-735-437-300N/A
3/31/20221,852-745-330-199N/A
12/31/20211,767-596-238-102N/A
9/30/20211,760-793-11734N/A
6/30/20211,712-82930156N/A
3/31/20211,546-72019109N/A
12/31/20201,491-82471136N/A
9/30/20201,321-327-890N/A
6/30/20201,131-165-238-111N/A
3/31/20201,062-136-262-87N/A
12/31/2019876-213-284-112N/A
9/30/2019724-216-271-88N/A
6/30/2019623-221N/A-62N/A
3/31/2019526-219N/A-105N/A
12/31/2018454-175N/A-69N/A
9/30/2018399-143N/A-69N/A
6/30/2018353-124N/A-70N/A
3/31/2018308-119N/A-77N/A
12/31/2017266-114N/A-72N/A
9/30/2017214-130N/A-98N/A
6/30/2017169-141N/A-118N/A
3/31/2017133-155N/A-121N/A
12/31/201699-167N/A-130N/A
9/30/201679-170N/A-133N/A
6/30/201663-175N/A-145N/A
3/31/201650-169N/A-141N/A
12/31/201539-158N/A-134N/A
9/30/201527-150N/A-135N/A
6/30/201514-139N/A-119N/A
3/31/20156-120N/A-104N/A
12/31/20142-100N/A-81N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EXAS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.3%).

Earnings vs Market: EXAS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EXAS is expected to become profitable in the next 3 years.

Revenue vs Market: EXAS's revenue (10.6% per year) is forecast to grow faster than the US market (10.4% per year).

High Growth Revenue: EXAS's revenue (10.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: EXAS's Return on Equity is forecast to be low in 3 years time (14.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/21 04:35
End of Day Share Price 2025/11/21 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Exact Sciences Corporation is covered by 44 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Bruce JacksonBenchmark Company